Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Global Neurodegeneration Proteomics Consortium: biomarker and drug target discovery for common neurodegenerative diseases and aging

15 Jul 2025

Abstract excerpt

More than 57 million people globally suffer from neurodegenerative diseases, a figure expected to double every 20 years. Despite this growing burden, there are currently no cures, and treatment options remain limited due to disease heterogeneity, prolonged preclinical and prodromal phases, poor understanding of disease mechanisms, and diagnostic challenges. Identifying novel biomarkers is crucial for improving...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer's disease research and treatments
Share to Amyotrophic Lateral Sclerosis Research
Share to Parkinson's Disease Mechanisms and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40665048
DOI: 10.1038/s41591-025-03834-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Global Neurodegeneration Proteomics Consortium: biomarker and drug target discovery for common neurodegenerative diseases and agingPMID 40665048Read ↗

Mapping the circulating proteome across neurodegeneration: A harmonized, consortium-scale framework for uncovering molecular pathophysiologySemantic proximity Read ↗

Identification of Novel Biomarkers for Alzheimer’s Disease and Related Dementias Using Unbiased Plasma ProteomicsSemantic proximity Read ↗

Multi-cohort cerebrospinal fluid proteomics identifies robust molecular signatures across the Alzheimer disease continuumSemantic proximity Read ↗

Proteomic landscape of Alzheimer’s disease: emerging technologies, advances and insights (2021 – 2025)Semantic proximity Read ↗

Multi-tissue proteomic signatures of Alzheimer’s disease: a systematic investigation in brain, CSF, blood and an exploratory study in tearsSemantic proximity Read ↗

Proteomic landscape of Alzheimer’s Disease: novel insights into pathogenesis and biomarker discoverySemantic proximity Read ↗

Deep Plasma Proteomics Reveals Shared and Disease-Specific Molecular Signatures in Alzheimer’s Disease and Frontotemporal DementiaSemantic proximity Read ↗

Identification of conserved proteomic networks in neurodegenerative dementiaSemantic proximity Read ↗

Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's diseaseSemantic proximity Read ↗

Mapping Parkinson’s Disease Progression through Deep Plasma Proteomics and Functional GenomicsSemantic proximity Read ↗

Large-scale Deep Proteomic Analysis in Alzheimer’s Disease Brain Regions Across Race and EthnicitySemantic proximity Read ↗

Network Analysis of the Cerebrospinal Fluid Proteome Reveals Shared and Unique Differences Between Sporadic and Familial Forms of Amyotrophic Lateral SclerosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.